Physician profile
Jon D Olson
NPI 1619966819
$18,970.93
in general payments reported to CMS, 2019-2025
58 companies · $3,716 in 2025
The $3,716 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,097 · 2020: $2,038 · 2021: $2,835 · 2022: $2,186 · 2023: $2,766 · 2024: $3,333 · 2025: $3,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,641 · Consulting Fee: $150 · Education: $24.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,640.67 |
| Consulting Fee | $150.00 |
| Education | $24.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,494.03 | 2019-2025 | |
| Biogen, INC. | $1,342.09 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Novocure INC. | $1,132.21 | 2020-2025 | Optune, Optune Gio |
| Amgen INC. | $999.16 | 2019-2025 | Uplizna |
| Pfizer INC. | $909.86 | 2019-2025 | |
| Ucb, INC. | $818.48 | 2019-2025 | Briviact, Rystiggo |
| Celgene Corporation | $807.31 | 2021-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $694.39 | 2019-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $691.94 | 2019-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $630.26 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $584.60 | 2019-2025 | Nuplazid |
| Emd Serono, INC. | $506.19 | 2019-2025 | Mavenclad, Mavenclad |
| Argenx US, INC. | $500.38 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $482.21 | 2020-2025 | Austedo Xr |
| Tg Therapeutics, INC. | $477.65 | 2023-2025 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $425.93 | 2019-2025 | Gamunex-C |
| Csl Behring | $415.47 | 2019-2025 | Hizentra |
| Sk Life Science, INC. | $370.58 | 2020-2025 | |
| Allergan, INC. | $361.12 | 2020-2021 | |
| Acorda Therapeutics, INC | $337.09 | 2019-2023 | Inbrija |
| Lundbeck LLC | $331.07 | 2019-2025 | Vyepti, Rexulti |
| Supernus Pharmaceuticals, INC. | $283.87 | 2019-2021 | |
| Ge Healthcare | $252.46 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $244.74 | 2019-2020 | |
| Lilly USA, LLC | $237.85 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Genentech USA, INC. | $232.01 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Amneal Pharmaceuticals LLC | $203.03 | 2019-2024 | Rytary |
| Genzyme Corporation | $189.42 | 2019-2025 | |
| Mdd US Operations, LLC | $183.90 | 2019-2024 | Apokyn, Xadago, Apokyn |
| Otsuka America Pharmaceutical, INC. | $175.53 | 2023-2025 | Rexulti, Nuedexta |
| Eisai INC. | $173.63 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $134.78 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $130.30 | 2021 | |
| Springworks Therapeutics, INC. | $111.31 | 2025 | Gomekli |
| Avanir Pharmaceuticals, INC. | $105.47 | 2019-2021 | |
| Genentech, INC. | $102.01 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| E.R. Squibb & Sons, L.L.C. | $100.04 | 2020-2021 | |
| Neurelis, INC. | $94.99 | 2020-2025 | Valtoco |
| Janssen Pharmaceuticals, INC | $87.49 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $78.69 | 2022-2025 | Inbrija, Ampyra, Xeomin |
| Ipsen Biopharmaceuticals, INC | $72.69 | 2019-2023 | Dysport |
| Takeda Pharmaceuticals U.S.A., INC. | $66.66 | 2023-2024 | Gammagard, Hyqvia |
| Jazz Pharmaceuticals INC. | $58.99 | 2019 | |
| Janssen Biotech, INC. | $55.46 | 2025 | |
| Ani Pharmaceuticals, INC. | $38.59 | 2024-2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $34.70 | 2020-2022 | |
| Piramal Critical Care | $32.10 | 2022-2023 | |
| Ceribell, INC. | $25.24 | 2022 | |
| Upsher-Smith Laboratories LLC | $25.06 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.58 | 2019 | |
| Gt Medical Technologies, INC | $20.05 | 2021 | |
| Adamas Pharmaceuticals, INC. | $18.65 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.20 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $15.89 | 2021 | |
| Horizon Therapeutics Plc | $12.19 | 2021 | |
| Insightec,INC | $11.94 | 2024 | Exablate |
| Strongbridge US INC. | $11.40 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.